LPGA, Takeda and Blue Bay

Rio Takeda of Japan shoots a blistering 8-under 64 in China to win her second LPGA title
Rio Takeda shot a blistering 8-under 64 to win the LPGA’s Blue Bay tournament by six shots ahead of Minjee Lee of Australia.
Rio Takeda runs off with Blue Bay win for second LPGA title
Rio Takeda shot a blistering 8-under 64 to win the LPGA's Blue Bay tournament by six shots ahead of Minjee Lee.
Rio Takeda wins Blue Bay LPGA in dominating fashion, first rookie to win on LPGA since 2023
Rio Takeda hinted at what she was capable of last fall. She proved it Sunday in China. The 21-year-old rookie from Japan closed in 8-under 64, the best round of the day at Jian Lake Blue Bay Golf Course,
Rio Takeda takes a 2-shot lead into the final round of the LPGA tournament in China
Rio Takeda of Japan shot a 3-under 69 to hold a two-shot lead after three rounds of the LPGA’s Blue Bay tournament on China’s southern island of Hainan.
Rio Takeda of Japan cards blistering 8-under 64 in China to win her second LPGA title
SANYA, China — Rio Takeda shot a blistering 8-under 64 on Sunday to win the LPGA’s Blue Bay tournament by six shots ahead of Minjee Lee of Australia, the second LPGA title for the young Japanese player.
Rio Takeda fires 64 at Blue Bay, captures second LPGA Tour title
LPGA Tour rookie Rio Takeda carded an 8-under-par 64 on Sunday to cruise to a six-stroke victory at the Blue Bay LPGA on Hainan Island, China. Takeda, 21, captured her second LPGA Tour title after recording a bogey-free round to finish 17-under 271 at the Jian Lake Blue Bay Golf Course.
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Fierce Biotech14h
‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...
Why were zebras parachuting from the rafters at a recent Celtics game?
Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...
Fierce Biotech10d
Takeda's $300M bet on Protagonist's blood cancer drug pays off with phase 3 win
Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...
BioSpace10d
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
BioPharma Dive10d
Protagonist says Takeda-partnered drug succeeds in rare blood cancer
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Mass. man gets prison time for defrauding Takeda Pharmaceutical Co. of $2.3M
A Massachusetts man who, along with his girlfriend, defrauded Takeda Pharmaceutical Co. of $2.3 million and used the money to ...